WEHI-842   Click here for help

GtoPdb Ligand ID: 10616

PDB Ligand Antimalarial Ligand
Compound class: Synthetic organic
Comment: WEHI-842 was developed as a potent peptidomimetic inhibitor of Plasmodium plasmepsin V (PMV), a promising target for antimalarial drug development [2].

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 7
Rotatable bonds 25
Topological polar surface area 219.49
Molecular weight 669.38
XLogP 3.57
No. Lipinski's rules broken 3
Click here for help
Canonical SMILES NC(=NOCC[C@@H](C(=O)N[C@H](C(=O)N[C@H]([C@H](CC(=O)NCCc1ccccc1)O)CC(C)C)C(C)C)NC(=O)OCc1ccccc1)N
Isomeric SMILES NC(=NOCC[C@@H](C(=O)N[C@H](C(=O)N[C@H]([C@H](CC(=O)NCCc1ccccc1)O)CC(C)C)C(C)C)NC(=O)OCc1ccccc1)N
InChI InChI=1S/C34H51N7O7/c1-22(2)19-27(28(42)20-29(43)37-17-15-24-11-7-5-8-12-24)38-32(45)30(23(3)4)40-31(44)26(16-18-48-41-33(35)36)39-34(46)47-21-25-13-9-6-10-14-25/h5-14,22-23,26-28,30,42H,15-21H2,1-4H3,(H,37,43)(H,38,45)(H,39,46)(H,40,44)(H4,35,36,41)/t26-,27-,28-,30-/m0/s1
Guide to Malaria Pharmacology Comments
Future progression of peptidomimetic Plasmodium plasmepsin V inhibitors, such as WEHI-842, through the antimalarial drug development pipeline will require improvements to their biochemical and pharmacokinetic properties. The 100-fold reduction in potency observed between isolated enzyme and cultured parasites could lead to unacceptable dosing levels in vivo. This loss of potency in cell-based assays may be explained by the finding, from functional genetics studies, that nearly all cellular PMV must be inhibited before parasite-killing effects are observed [4].
Patent WO2016197190 relates to a class of compounds based on WEHI-842 [1].

Potential Target/Mechanism Of Action: WEHI-842 inhibits Plasmodium PMV (see Clinical data tab for further details).